Production of recombinant adeno-associated virus 5 using a novel self-attenuating adenovirus production platform

Abstract excerpt

Recombinant adeno-associated virus (rAAV) has become a prominent vector for clinical use. Despite an increase in successful clinical outcomes, the amount of high-quality rAAVs required for clinical trials and eventual commercial demand is difficult to produce, especially for genetic diseases that are prevalent or require high doses. Many groups are focused on establishing production processes that can produce...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Viral gastroenteritis research and epidemiology
• Share to Viral Infectious Diseases and Gene Expression in Insects
• Share to Virus-based gene therapy research